Phase 2 Ovarian Cancer Trial, By Invitation NCT03393962 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, By Invitation

NCT03393962
By Invitation Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must provide written agreement to take part before any trial-related procedures begin.
  • The person must be older than 10 years of age.
  • The person must have a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work).
  • The person must be expected to live for at least 12 weeks.
  • The person must have a confirmed diagnosis of high-risk gynecological cancer (specifically FIGO Stage II–IV), proven through tissue testing.
  • The person must not be pregnant, and must be using appropriate contraception if there is any possibility of becoming pregnant.
  • The person must have adequate blood cell counts, specifically: white blood cells (neutrophils) at or above 1,000/mm³, and platelets at or above 100,000/mm³.
  • The person must have kidney and liver function within acceptable ranges, including: creatinine no more than twice the upper normal limit; bilirubin no more than twice the upper normal limit (a slightly higher bilirubin level may be accepted if a condition called Gilbert's syndrome has been diagnosed); liver enzymes (AST and ALT) no more than twice the upper normal limit; and another liver marker (alkaline phosphatase) no more than five times the upper normal limit.
  • The person must have tested negative for HIV and Hepatitis C virus.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a type of ovarian tumour considered "borderline" (low malignant potential) rather than fully cancerous.
  • People who have unexplained free air in the abdomen (not caused by a recent medical procedure or surgery).
  • People who have previously received any treatment involving adoptive T cell therapy (a type of immune cell treatment).
  • People who have received immune-suppressing medications within the 14 days before the trial start date.
  • People who have had a minor surgical procedure within 2 days before the trial start date, including procedures such as placing a central venous line, tumour biopsy, or needle aspiration.
  • People who are pregnant or currently breastfeeding.
  • People whose bone marrow is not producing enough blood cells, specifically: neutrophils below 1,000/mm³; platelets below 100,000/mm³; or haemoglobin below 9 g/dL.
  • People whose liver or kidney function falls outside acceptable limits, including: total bilirubin above 1.5 times the upper normal limit; AST and ALT above 2.5 times the upper normal limit (or above 5 times the upper normal limit if cancer has spread to the liver); alkaline phosphatase above 2.5 times the upper normal limit; creatinine above 2.0 mg/dL; or protein in the urine above certain measured levels (confirm with trial site for full urine testing details).
  • People who have a serious active infection currently being treated with intravenous (IV) antibiotics.
  • People who have tested positive for Hepatitis C, HIV, syphilis (Treponema pallidum), or tuberculosis (TB).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
31 January 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety of OC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov